Medikine employs a peptide-based approach to discover novel agonists of heterodimeric cytokine receptors. Medikine's lead project is based on a peptide that activates IL-2Rβ/γ - a validated target for immuno-oncology therapy. The peptide has sub-nM potency in IL-2 responsive cells including human lymphocyte subpopulations, is unrelated to the structure of IL-2, and does not bind to IL-2Rα. The peptide is active when fused to an Fc domain (to act as a monospecific IL-2 agent) and full IgG antibodies (to create a bi-specific agent). Medikine plans to finalize selection of an IND-candidate later this year.